Literature DB >> 33762130

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.

Angelo Ruggiero1, Gabriella Fabbrocini2, Eleonora Cinelli2, Matteo Megna2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33762130     DOI： 10.1016/j.jaad.2021.01.025

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  15 in total

1.  How to decrease systemic corticosteroids in pemphigus patients under rituximab.

Authors:  Fabrizio Martora; Vincenzo Picone; Gabriella Fabbrocini; Matteo Megna
Journal:  Health Sci Rep       Date:  2022-06-06

2.  PSORS1 Locus Genotyping Profile in Psoriasis: A Pilot Case-Control Study.

Authors:  Noha Z Tawfik; Hoda Y Abdallah; Ranya Hassan; Alaa Hosny; Dina E Ghanem; Aya Adel; Mona A Atwa
Journal:  Diagnostics (Basel)       Date:  2022-04-20

3.  Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.

Authors:  Marloes E Van Muijen; Sarah E Thomas; Hans M M Groenewoud; Marisol E Otero; Paul M Ossenkoppele; Marcellus D Njoo; Sharon R P Dodemont; Else N Kop; Maartje A M Berends; Marjolein I A Koetsier; Johannes M Mommers; John E M Körver; Ron A Tupker; Marjolein S De Bruin-Weller; Lizelotte J M T Weppner-Parren; Bas Peters; Marloes M Kleinpenning; Astrid L A Kuijpers; W Peter Arnold; Paula P M Van Lümig; Juul M P A Van den Reek; Elke M G J De Jong
Journal:  Acta Derm Venereol       Date:  2022-05-16       Impact factor: 3.875

Review 4.  Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.

Authors:  Angelo Ruggiero; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-06-08

5.  Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.

Authors:  A Ruggiero; G Fabbrocini; E Cinelli; S S Ocampo Garza; E Camela; M Megna
Journal:  Clin Exp Dermatol       Date:  2021-11-17       Impact factor: 4.481

6.  Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

Authors:  Giacomo Caldarola; Arianna Zangrilli; Nicoletta Bernardini; Mauro Bavetta; Clara De Simone; Dario Graceffa; Claudio Bonifati; Sara Faleri; Domenico Giordano; Marco Mariani; Adriana Micheli; Gaia Moretta; Gianluca Pagnanelli; Vincenzo Panasiti; Alessia Provini; Antonio Richetta; Ketty Peris; Luca Bianchi
Journal:  Dermatol Ther       Date:  2022-04-13       Impact factor: 3.858

7.  Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.

Authors:  Andrew Blauvelt; Melinda Gooderham; Christopher E M Griffiths; April W Armstrong; Baojin Zhu; Russel Burge; Gaia Gallo; Jiaying Guo; Alyssa Garrelts; Mark Lebwohl
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-23

Review 8.  Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.

Authors:  Angelo Ruggiero; Fabrizio Martora; Vincenzo Picone; Laura Marano; Gabriella Fabbrocini; Claudio Marasca
Journal:  Biomedicines       Date:  2022-02-16

Review 9.  Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.

Authors:  Angelo Ruggiero; Vincenzo Picone; Fabrizio Martora; Gabriella Fabbrocini; Matteo Megna
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-16

10.  Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.

Authors:  Matteo Megna; Luca Potestio; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Psoriasis (Auckl)       Date:  2022-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.